Vericel Corporation (NASDAQ: VCEL) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Valuation and Earnings

This table compares Vericel Corporation and BioMarin Pharmaceutical’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Vericel Corporation $53.77 million 3.02 -$20.03 million ($1.10) -4.50
BioMarin Pharmaceutical $1.20 billion 13.87 -$106.70 million ($1.09) -87.11

Vericel Corporation has higher revenue, but lower earnings than BioMarin Pharmaceutical. BioMarin Pharmaceutical is trading at a lower price-to-earnings ratio than Vericel Corporation, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for Vericel Corporation and BioMarin Pharmaceutical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vericel Corporation 0 0 3 0 3.00
BioMarin Pharmaceutical 0 7 15 0 2.68

Vericel Corporation currently has a consensus price target of $6.33, indicating a potential upside of 27.95%. BioMarin Pharmaceutical has a consensus price target of $110.80, indicating a potential upside of 16.69%. Given Vericel Corporation’s stronger consensus rating and higher probable upside, equities analysts clearly believe Vericel Corporation is more favorable than BioMarin Pharmaceutical.

Profitability

This table compares Vericel Corporation and BioMarin Pharmaceutical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vericel Corporation -50.27% N/A -59.46%
BioMarin Pharmaceutical -15.54% -5.77% -4.00%

Risk & Volatility

Vericel Corporation has a beta of 3.07, meaning that its stock price is 207% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500.

Institutional & Insider Ownership

33.8% of Vericel Corporation shares are owned by institutional investors. Comparatively, 97.5% of BioMarin Pharmaceutical shares are owned by institutional investors. 3.3% of Vericel Corporation shares are owned by insiders. Comparatively, 2.5% of BioMarin Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

BioMarin Pharmaceutical beats Vericel Corporation on 7 of the 13 factors compared between the two stocks.

Vericel Corporation Company Profile

Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

Receive News & Ratings for Vericel Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel Corporation and related companies with MarketBeat.com's FREE daily email newsletter.